MCL-135 BRUIN MCL-321, a Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated, BTK Inhibitor Naïve Mantle Cell Lymphoma (Trial in Progress)
Rodrigo Ito, Toby A. Eyre, Nirav N. Shah, Steven Le Gouill, Martin Dreyling, Elisabeth Vandenberghe, Wojciech Jurczak, Yucai Wang, Chan Y. Cheah, Mitul Gandhi, Christopher Chay, Jeff Sharman, David J. Andorsky, Yuqin Song, Amy Stark, Valerie Muthig, Michael L. Wang
Dive into the research topics of 'MCL-135 BRUIN MCL-321, a Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated, BTK Inhibitor Naïve Mantle Cell Lymphoma (Trial in Progress)'. Together they form a unique fingerprint.